[Skip to Content]
[Skip to Content Landing]
June 1979

Oropharyngeal Candidiasis Treated With a Troche Form of Clotrimazole

Author Affiliations


From the Department of Developmental Therapeutics, The University of Texas System Cancer Center M. D. Anderson Hospital and Tumor Institute, Houston.

Arch Intern Med. 1979;139(6):656-657. doi:10.1001/archinte.1979.03630430036012

A randomized double-blind trial was conducted to assess the local effectiveness and safety of a troche form of clotrimazole in the treatment of oropharyngeal candidiasis in cancer patients. One half of the patients received one 10-mg troche and the other half received one 50-mg troche, five times a day for two weeks. Clinical cures were observed in 50 episodes, resulting in a cure rate of 96%. The median duration of oropharyngeal candidiasis after the start of therapy was three days in those treated with the 50-mg troche and four days in those who had received the 10-mg troche. Side effects were minimal, and only one patient experienced nausea and abdominal pain. Both the 10-mg and 50-mg troches appear to be efficacious and safe, but the 50-mg dose may be preferable because it is somewhat more effective without additional toxicity.

(Arch Intern Med 139:656-657, 1979)